- The second interim analysis, which occurred after 12 patients completed 24 weeks of treatment, indicated the ongoing trial should continue as planned, which is currently ongoing.
Catalyst
Slingshot members are tracking this event:
Interim Phase 2 data for RP103 in Mitochondrial Diseases due Q2 of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RPTP |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 04, 2016
Occurred Source:
http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID=983090
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim Clinical Data, Phase 2 Data, Rp103, Mitochondrial Diseases
